Merck speeds its KRAS into the colorectal front line
The move follows promising but early data presented at ASCO.
ASCO 2025 – Exelixis’s son of Cabometyx improves
In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.
ASCO 2025 preview – KRAS challengers assemble
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
ASCO 2025 preview – Kura looks similar to Syndax
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
ASCO 2025 preview – Itovebi strengthens its first-line claim
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
Relay pulls ahead of Lilly
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
Avistone’s Met challenge
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
Erasca enters its pan-RAS era
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
